Research Article

Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)

Yvonne A Efebera*, Amy S Ruppert, Apollinaire Ngankeu, Sabrina Garman, Prasanthi Kumchala, Alan Howard, Steven M Devine, Parvathi Ranganathan and Ramiro Garzon

Published: 08/16/2019 | Volume 2 - Issue 1 | Pages: 079-082

Letter to Editor

Allogeneic hematopoietic stem cell transplant (alloHSCT) is a curative treatment for many hematologic malignancies. Unfortunately, about  30-50% of all recipients undergoing alloHSCT develop acute graft-versus-host-disease (aGVHD), which is associated with high morbidity and mortality [1,2].Treatment of aGVHD involves the use of immune suppressive drugs such as high dose of steroids that leads to further immunosuppression and risk for opportunistic infections. Often patients are refractory to steroids therapy making the prognosis dismal. Thus, it is critical to identify robust biomarkers to detect aGVHD before onset of clinical symptoms so that therapeutic strategies can be implemented that may result in better treatment responses and less toxicity.

Read Full Article HTML DOI: 10.29328/journal.ijbmr.1001007 Cite this Article


  1. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012; 12: 443-458 PubMed:
  2. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 373: 1550-1561. PubMed:
  3. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood. 2013; 121: 585-594. PubMed:
  4. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010; 2: 13ra2. PubMed:
  5. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009; 113: 273-278. PubMed:
  6. Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015; 125: 3183-3192. PubMed:
  7. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013; 369: 529-539. PubMed:
  8. Ali AM, DiPersio JF, Schroeder MA. The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review. Biol Blood Marrow Transplant. 2016; 22: 1552-1564. PubMed:
  9. Paczesny S, Levine JE, Braun TM, Ferrara JL. Plasma biomarkers in graft-versus-host disease: a new era? Biol Blood Marrow Transplant. 2009; 15: 33-38. PubMed:
  10. Xiao B, Wang Y, Li W, Baker M, Guo J, et al. Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. Blood. 2013; 122: 3365-3375. PubMed:
  11. Wang Y, Zhao X, Ye X, Luo H, Zhao T, et al. Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease. Ann Hematol. 2015; 94: 1505-1514. PubMed:
  12. Xie LN, Zhou F, Liu XM, Fang Y, Yu Z, et al. Serum microRNA155 is increased in patients with acute graft-versus-host disease. Clin Transplant. 2014; 28: 314-323. PubMed:
  13. Atarod S, Ahmed MM, Lendrem C, Pearce KF, Cope W, et al. miR-146a and miR-155 Expression Levels in Acute Graft-Versus-Host Disease Incidence. Front Immunol. 2016; 7: 56. PubMed:
  14. Chen S, Smith BA, Iype J, Prestipino A, Pfeifer D, et al. MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. Blood. 2015; 126: 103-112. PubMed:
  15. Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood. 2012; 119: 4786-4797. PubMed:
  16. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010; 116: 5111-5118. PubMed: